The HbS variant that causes sickle cell disease arises from which change in beta-globin?

Glutamic acid replaced by valine at position 6. The HBB gene makes beta-globin. In HbS, glutamic acid is swapped for valine at position 6 (Glu6Val). The first option reverses the swap. The other options name wrong amino acids or a wrong position. Read more: SciTech0214 Sickle Cell Anaemia and India's Elimination Mission 2047

Consider the following statements. 1. Sickle cell trait (HbAS) means one HbS gene and one normal HbA gene. 2. If both parents are carriers, each child has a 25% chance of HbSS. 3. Carriers usually have severe symptoms like those of HbSS. Which of the statements given above is/are correct?

1 and 2 only. Statements 1 and 2 are correct. Two carrier parents give 25% HbSS, 50% carrier and 25% unaffected. Statement 3 is wrong because carriers usually have no symptoms. Read more: SciTech0214 Sickle Cell Anaemia and India's Elimination Mission 2047

Which statement about the National Sickle Cell Anaemia Elimination Mission is correct?

It was launched by the PM at Shahdol, Madhya Pradesh, on 1 July 2023, aiming at elimination by 2047. The PM launched the mission at Shahdol, Madhya Pradesh, on 1 July 2023. The target is elimination as a public health problem by 2047 (Amrit Kaal). Screening covers ages 0-40 in 278 districts. The other options change the venue, age band or target year. Read more: SciTech0214 Sickle Cell Anaemia and India's Elimination Mission 2047

Consider the following statements about BIRSA 101. 1. It was launched on 19 November 2025 as India's first indigenous CRISPR-based gene therapy for sickle cell disease. 2. CSIR-IGIB and Serum Institute of India signed a technology transfer agreement for it. 3. IGIB says Phase I clinical trials are expected to begin in 2027. 4. It has already received CDSCO approval for patient use. How many of the statements given above are correct?

Only three. Statements 1, 2 and 3 are correct. Statement 4 is wrong. No completed human trial or CDSCO approval has been found up to 1 November 2026. BIRSA 101 is an ex vivo therapy still before trials. Read more: SciTech0214 Sickle Cell Anaemia and India's Elimination Mission 2047

Assertion (A): The HbS gene has persisted in malaria-prone populations. Reason (R): Sickle cell trait gives partial protection against severe falciparum malaria. Which one is correct?

Question 1 of 5

Question 2 of 5

Question 3 of 5

Question 4 of 5

Question 5 of 5

Assertion (A): The HbS gene has persisted in malaria-prone populations. Reason (R): Sickle cell trait gives partial protection against severe falciparum malaria. Which one is correct?

Keep practicing

Beyond the answer

Share your thoughts Cancel reply